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Abstract : Introduction : Cystatin C (CysC) is biomarker for early detection of acute kidney injury (AKI). How-
ever, there is limited evidence in decompensated cirrhotic patients without AKI at admission. This study aimed 
to assess CysC as a predictor of 90-day mortality. Methods : Decompensated cirrhotic patients without AKI were 
prospectively enrolled. CysC and creatinine were measured within 24 hours of admission and compared be-
tween patients with in-hospital complications (AKI, hepatorenal syndrome (HRS), acute-on-chronic liver failure 
(ACLF)) vs. those without, and survivors vs. non-survivors. The AUROC and cut-off point of CysC in predicting 
90-day mortality were determined. Results : Of 137 decompensated cirrhotic patients, 46 without AKI at admis-
sion were included (58.7% male, age 60.8 ± 11.2years, MELD 13.1 ± 5.1, ChildA / B / C 43.5% / 39.1% / 17.4%). The mean 
CysC level tended to be higher in patients with ACLF (1.52 ± 0.60 vs. 1.11 ± 0.28, p = 0.05), and significantly higher 
in non-survivors than survivors (1.61 ± 0.53 vs. 1.08 ± 0.28, p = 0.013). The 90-day mortality rate was 21.7%. After ad-
justing with age and bacterial infection on admission, CysC  level  ≥ 1.25 mg / L was significantly associated with 
90-day mortality. The CysC cut-off level  ≥ 1.25 mg / L provided 80% sensitivity and 75% specificity for predicting 
90-day mortality. Conclusion : Plasma CysC within 24 hours could be used as a predictor for 90-day mortality and 
development of ACLF in decompensated cirrhotic patients. J. Med. Invest. 68 : 302-308, August, 2021
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INTRODUCTION
 
Acute kidney injury (AKI) is a common complication associat-
ed with high morbidity and mortality in decompensated cirrhotic 
patients (1, 2). Approximately 20% of hospitalized patients with 
cirrhosis experience deterioration of renal function predomi-
nantly caused by prerenal azotemia and acute tubular necrosis 
(3). Early diagnosis of AKI in cirrhotic patients is essential to 
prevent its progression and reduce mortality. Serum creatinine, 
an indicator of renal function, is widely used for the diagnosis of 
AKI in clinical practice. However, several limitations should be 
taken into consideration as serum creatinine might overestimate 
renal function, especially in cirrhotic patients (4, 5). Falsely 
decreased creatinine in cirrhosis can be resulted from 4 main 
reasons : diminished creatinine production due to sarcopenia 
(6) ; dilution effect from increased volume of distribution (7) ; in-
creased renal tubular creatinine excretion (8) ; bilirubin inter-
ference in creatinine estimation (9). Therefore, these drawbacks 
have inspired researchers to find new biomarkers to provide 
more accurate assessment of renal function in cirrhotic patients.
Cystatin C (CysC) is non-glycosylated, low-molecular-weight 
protein produced by all nucleated cells at a constant rate. Since 
1994, CysC has been introduced as a surrogate marker for de-
termining glomerular filtration rate (10). CysC is freely filtered 
by glomerulus, completely reabsorbed, and metabolized by prox-
imal tubular cells. In contrast to creatinine, CysC is not affected 
by demographic factors and muscle mass (11). These properties 
make CysC a good candidate for estimating renal function in cir-
rhotic patients. Previous studies suggested that CysC might be a 
predictor of early renal dysfunction in cirrhotic patients (12-16). 
Moreover, the CysC level of more than 1.5 mg / L could predict 
90-day mortality in decompensated cirrhotic patients with sen-
sitivity and specificity of 73.3% and 52.5%, respectively (12). The 
changes in CysC level also demonstrated stronger association 
with dialysis or mortality than serum creatinine in cirrhotic 
patients with AKI (16). 
Until now, there have been limited data regarding prognostic 
ability of plasma CysC in hospitalized decompensated cirrhotic 
patients. This study aimed to determine the efficacy of plasma 
CysC as a predictor of morbidity and mortality in acutely de-
compensated cirrhotic patients who had no AKI on the day of 
admission.
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MATERIALS AND METHODS
Study design and population
This prospective observational study was conducted at 
Thammasat University Hospital between October 1, 2017 and 
November 30, 2019. The inclusion criteria were hospitalized 
patients diagnosed with acute decompensated cirrhosis aged 
between 18 and 80 years old. The exclusion criteria were the 
presence of AKI on the day of admission, chronic kidney disease 
(CKD), pregnancy, hypothyroidism or hyperthyroidism, history 
of steroid use, previous liver or kidney transplantation, hepato-
cellular carcinoma, HIV infection, receiving immunosuppressive 
drugs for any disease except severe alcoholic hepatitis, or refusal 
to participate in the study. 
This study received ethical approval by the Human Research 
Ethics Committee of Thammasat University, Thailand and was 
conducted according to the good clinical practice guideline, as 
well as the Declaration of Helsinki. Written informed consent 
was obtained from all participants. The patient’s relative could 
provide written informed consent instead of the patient himself 
in case of being diagnosed with hepatic encephalopathy. The 
informed consent was then requested from the patient after 
the resolution of hepatic encephalopathy for continuation in the 
study. 
Study protocol
All patients were included in this study within 24 hours of 
admission. Demographic data, etiologies of cirrhosis, underlying 
medical conditions, history of present illness, physical examina-
tion, and treatment outcomes were recorded. Laboratory results 
including a complete blood count, a comprehensive metabolic 
panel, coagulation tests, hemoculture, ascitic fluid analysis and 
culture, urinalysis and urine culture were recorded. The Child-
Pugh score, the model for end-stage liver disease (MELD) score, 
and MELD-Na score were calculated to assess severity of liver 
impairment. Blood samples for determining plasma CysC and 
serum creatinine were collected from each patient at the same 
time within 24 hours of admission. At least 1-ml plasma sample 
was obtained by centrifugation and then stored at -20°C until 
CysC analysis was performed by using nephelometry (13). All pa-
tients received standard treatment for acute decompensated cir-
rhosis. The 90-day mortality rate was prospectively evaluated. 
The primary aim was to determine the efficacy of plasma 
CysC as a predictor of 90-day mortality in acutely decompensat-
ed cirrhotic patients without AKI on the day of admission. The 
secondary aim was to evaluate the efficacy of plasma CysC as a 
predictor of in-hospital AKI, hepatorenal syndrome (HRS) and 
acute-on-chronic liver failure (ACLF) in acutely decompensated 
cirrhotic patients.
Definitions 
Acute decompensation was defined as an acute devel-
opment of one or more of the following complications : ascites, 
hepatic encephalopathy, gastrointestinal bleeding, or bacterial 
infection in a patient with cirrhosis (17). 
Acute-on-chronic liver failure (ACLF) was defined ac-
cording to the diagnostic criteria established in the CANONIC 
study (17). 
Acute kidney injury (AKI) was defined as an increase in 
serum creatinine of  ≥ 0.3 mg / dL within 48 hours ; or a percent-
age increase in serum creatinine of  ≥ 50% from baseline which 
is known or presumed to have occurred within the previous 7 
days (9). 
Hepatorenal syndrome (HRS) was defined as the diagno-
sis of cirrhosis and ascites in concurrent with the diagnosis of 
AKI. In addition, the diagnostic criteria included no response of 
AKI after 2 consecutive days of diuretic withdrawal and plasma 
volume expansion with 1 gram of albumin per kilogram of body 
weight, absence of shock, no current or recent use of nephrotoxic 
drugs, and no macroscopic signs of structural kidney injury (9). 
Glomerular filtration rate (GFR) was calculated by using 
the chronic kidney disease epidemiology collaboration (CKD-
EPI) equation based on serum creatinine, or CysC (18).
Chronic kidney disease (CKD) was defined as either struc-
tural or functional renal abnormalities. The presence of either 
one of markers for kidney damage (e.g., albuminuria, urine sed-
iment abnormalities) or decreased GFR < 60 ml / min / 1.73 m2 for 
> 3 months is considered as CKD (19).
Statistical analysis
All statistical analyses were performed by using STATA soft-
ware version 12.0 (Stata Corp, Texas, USA). The demographic 
data and clinical characteristics were analyzed by Fisher’s exact 
test, or Chi-square test where appropriate. Laboratory results 
were compared between 90-day survivors and non-survivors 
using Student’s t-test. Plasma CysC level was presented as mean 
and standard deviation and evaluated for association with the 
development of in-hospital complications (AKI, HRS, ACLF), 
and 90-day mortality. The receiver operating characteristic 
(ROC) curve analysis of CysC for predicting 90-day mortality 
was performed, and the optimal cut-off point which yielded the 
highest sensitivity and specificity was selected. The area under 
the ROC curve (AUROC) of CysC and MELD score for predict-
ing 90-day mortality was compared. Statistical significance was 
defined as p-value of less than 0.05.
Sample size for two-sample comparison of means was calcu-
lated in order to achieve 90% power using a two-sided test with 
an alpha level of 0.05. The means of plasma CysC used in the 
calculation were from the previous study in which patients who 
survived had a mean plasma CysC of 1.5 ± 0.23 mg / L, whereas 
patients who died within 90 days had a mean of 1.9 ± 0.33 mg / L 
(12). The estimated total sample size was at least 42.
RESULTS
Patient characteristics
Of 137 decompensated cirrhotic patients admitted during the 
study period, 91 patients (27 with AKI, 59 with chronic kidney 
disease, and 5 with hepatocellular carcinoma) were excluded 
from the study. A total of 46 patients were prospectively enrolled 
(27 men and 19 women) with a mean age of 60.8 ± 11.2 (range 40-
80) years. All patients were diagnosed with acute decompensat-
ed cirrhosis without AKI on the day of admission. The average 
serum creatinine within the previous 3 months before the study 
entry of all patients was 0.8 ± 0.2 mg / dl, meanwhile the previous 
urinary examination (available in 32 / 46 patients) showed no 
significant abnormalities (e.g., albuminuria, urine sediments). 
The most common causes of cirrhosis were alcohol (50%), chronic 
hepatitis B infection (17.4%) and non-alcoholic steatohepatitis 
(17.4%). There were 20 (43.5%), 18 (39.1%), and 8 (17.4%) patients 
classified as Child-Pugh class A, B, and C, respectively. The 
mean MELD and MELD-Na score were 13.1 ± 5.1 and 15.1 ± 5.4, 
respectively. The most common comorbidities were diabetes 
(39.1%), hypertension (34.8%), and dyslipidemia (17.4%), where-
as 18 (39.1%) patients had no comorbidity. Majority of patients 
had bacterial infection (37%), and portal hypertension-related 
gastrointestinal bleeding (34.8%) as presenting symptoms of 
decompensation. Baseline characteristics of all patients were 
demonstrated in the Table 1.
Laboratory results at baseline including complete blood count, 
renal and liver function test were demonstrated in the Table 2. 
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The mean serum creatinine was 0.85 ± 0.17 mg / dL, and mean 
plasma CysC was 1.20 ± 0.41 mg / L. The means of GFR estimat-
ed by serum creatinine and plasma CysC were 86.3 and 68.3 
ml / min, respectively. There was no significant difference of the 
mean CysC level according to Child-Pugh classes (1.09  ±  0.27 
mg / L for Child-Pugh A vs. 1.22 ± 0.33 mg / L for Child-Pugh B vs. 
1.41 ± 0.72 mg / L for Child-Pugh C, p = 0.164).
The 90-day mortality
There were 10 patients (21.7%) who died within 90 days. Six 
deaths were due to sepsis with multiorgan failure, two from 
massive gastrointestinal hemorrhage, and another two from 
ACLF with progressive liver deterioration. All 5 patients who 
developed in-hospital AKI died within 90 days, 4 of whom died 
during admission, while the other one survived and subsequent-
ly died 41 days after being discharged from hospital due to sepsis 
with multiorgan failure. Baseline characteristics along with 
laboratory results were compared between 90-day survivors and 
non-survivors as demonstrated in the Table 1 and 2. The mean 
age of non-survivors was significantly higher than survivors 
(70.1 ± 8.4 vs. 58.2 ± 10.5, p = 0.002). Alcoholic cirrhosis was more 
prevalent in survivors, whereas cirrhosis due to unidentified 
causes was more common in non-survivors. Non-survivors had 
significantly higher MELD-Na score than survivors (18.9 ± 6.6 
vs. 14.1 ± 4.6, p = 0.010). Meanwhile the MELD score was higher 
in non-survivor (15.2 ± 6.5 vs. 12.5 ± 4.6), however no statistical 
significance was reached (p = 0.136). The diagnosis of bacterial 
infection (70% vs. 27.8%, p = 0.025), and spontaneous bacterial 
peritonitis (SBP) (50% vs. 8.3%, p = 0.007) on current admission 
were more prevalent in non-survivors than survivors. In addi-
tion, the mean CysC level was 1.39 ± 0.42 mg / L in the group 
with bacterial infection compared to 1.08 ± 0.36 mg / L in the 
group without (p = 0.012).  The average length of hospital stay 
was 8 ± 7 days. Non-survivors had slightly longer average length 
of hospital stay than survivors (9.9 ± 9.5 days vs. 7.9 ± 6.7 days, 
p = 0.459).
Table 1.　Baseline and clinical characteristics of included patients and comparison between 90-day survivors and non-survivors






Male (%) 27 (58.7%) 23 (63.9%) 4 (40%) 0.277
Mean age 60.8 ± 11.2 58.2 ± 10.5 70.1 ± 8.4 0.002
Body mass index (kg / m2) 23.7 ± 4.2 23.6 ± 4.0 23.9 ± 5.1 0.855
Comorbidities
  Diabetes mellitus 18 (39.1%) 14 (38.9%) 4 (40%) 1.000
  Hypertension 16 (34.8%) 10 (27.8%) 6 (60%) 0.074
  Dyslipidemia 8 (17.4%) 4 (11.1%) 4 (40%) 0.055
  Cardiovascular disease 4 (8.7%) 2 (5.6%) 2 (20%) 0.201
  None 18 (39.1%) 15 (41.7%) 3 (30%) 0.717
Underlying liver diseases
Cirrhosis etiology
  Alcohol 23 (50.0%) 22 (61.1%) 1 (10%) 0.004
  Chronic hepatitis B 8 (17.4%) 7 (19.4%) 1 (10%) 0.664
  Chronic hepatitis C 6 (13.0%) 3 (8.3%) 3 (30%) 0.107
  NASH 8 (17.4%) 5 (13.9%) 3 (30%) 0.344
  Cryptogenic 4 (8.7%) 1 (2.8%) 3 (30%) 0.028
Child-Pugh class 0.616
  A 20 (43.5%) 17 (47.2%) 3 (30%)
  B 18 (39.1%) 13 (36.1%) 5 (50%)
  C 8 (17.4%) 6 (16.7%) 2 (20%)
MELD (Mean ± SD) 13.1 ± 5.1 12.5 ± 4.6 15.2 ± 6.5 0.136
MELD-Na (Mean ± SD) 15.1 ± 5.4 14.1 ± 4.6 18.9 ± 6.6 0.010
Previous decompensation 28 (60.9%) 22 (61.1%) 6 (60%) 1.000
Acute decompensation present on current admission
Bacterial infection 17 (37%) 10 (27.8%) 7 (70%) 0.025
SBP 8 (17.4%) 3 (8.3%) 5 (50%) 0.007
PHT-related 
gastrointestinal bleeding 16 (34.8%) 15 (41.7%) 1 (10%) 0.130
Hepatic encephalopathy 6 (13.0%) 5 (13.9%) 1 (10%) 1.000
Ascites 2 (4.3%) 2 (5.6%) 0 (0%) 1.000
*The p-value of < 0.05 represents significant difference between survivors and non-survivors.
Abbreviations : NASH = non-alcoholic steatohepatitis, MELD = model for end-stage liver disease, SBP = spontaneous bacterial peritoni-
tis PHT = portal hypertension
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All renal function parameters on the first day of admission 
in non-survivors were worse than survivors. Serum creatinine 
(0.97 ± 0.14 vs. 0.82 ± 0.16, p = 0.01) and plasma CysC (1.61 ± 0.53 
vs. 1.08 ± 0.28, p = 0.013) in non-survivors were significantly 
higher than survivors, while creatinine- and CysC-based glo-
merular filtration rate (GFR) were lower. International normal-
ized ratio (INR) was also higher in patients who died (1.90 ± 0.55 
vs. 1.42 ± 0.31, p = 0.024). Other laboratory results including 
complete blood count and liver function test were not significant-
ly different between 2 groups. 
Development of AKI, HRS, and ACLF
Five patients (10.9%) developed AKI during admission. The 
causes of AKI were prerenal azotemia (60%) and hepatorenal 
syndrome (40%). The mean of plasma CysC tended to be high-
er in patients who developed AKI (1.82 ± 0.71 vs. 1.12 ± 0.29 
mg / L, p = 0.093), whereas there was no significant difference 
of baseline serum creatinine between 2 groups  (0.94 ± 0.15 vs. 
0.84 ± 0.17 mg / dL, p = 0.214). Of the 5 patients with in-hospital 
AKI, all had normal serum creatinine, whereas 4 patients (80%) 
had elevated plasma CysC on the first day of admission. Two 
patients who developed HRS during admission had higher mean 
of plasma CysC than those without, however no statistical signif-
icance was reached (2.03 ± 1.00 vs. 1.16 ± 0.34 mg / L, p = 0.434). 
On the contrary, there was no significant difference of baseline 
serum creatinine between patients who developed HRS and 
those who did not (0.87 ± 0.21 vs. 0.85 ± 0.17 mg / dL, p = 0.892). 
ACLF were diagnosed in 10 patients (21.7%), 4 of whom died 
during admission. Half of all ACLF patients had renal failure as 
one of organ failure. The mean of plasma CysC tended to be high-
er in patients who developed ACLF (1.52 ± 0.60 vs. 1.11 ± 0.28 
mg / L, p = 0.05), whereas there was no significant difference 
in baseline serum creatinine between 2 groups  (0.93 ± 0.16 vs. 
0.83 ± 0.17 mg / dL, p = 0.102). 
 
Predictors of AKI, HRS, ACLF, and 90-day mortality
The ROC curve analysis showed that the AUROC of plas-
ma CysC in predicting 90-day mortality was 0.85 (95% CI 
0.71-0.97), which was marginally superior to the MELD score 
(AUROC 0.64, 95% CI 0.43-0.84, p = 0.04). The best cut-off 
value of plasma CysC for predicting 90-day mortality was ≥ 1.25 
mg / L, which yielded sensitivity and specificity of 80% and 75%, 
respectively. Patients with CysC of ≥ 1.25 mg / L demonstrated 
significant association with 90-day mortality (OR 12 ; 95%CI 
2.14-67.24, p = 0.005). 
In terms of in-hospital AKI, the AUROC curve of plasma 
CysC in predicting in-hospital AKI was 0.79 (95% CI 0.39-1.0). 
The cut-off value of plasma CysC ≥ 1.25 mg / L for predicting 
in-hospital AKI provided sensitivity and specificity of 80% 
and 68%, respectively. The AUROC curve of plasma CysC in 
predicting in-hospital ACLF was 0.75 (95% CI 0.56-0.93). The 
cut-off value of plasma CysC ≥ 1.25 mg / L for predicting in-hos-
pital ACLF yielded sensitivity and specificity of 70% and 72%, 
respectively. Patients with CysC of ≥ 1.25 mg / L demonstrated 
Table 2.　Laboratory findings of included patients and comparison between 90-day survivors and non-survivors







Hemoglobin (g / dL) 9.4 ± 2.2 9.6 ± 2.3 8.6 ± 2.5 0.205
WBC count (x109 / L) 8.4 ± 4.3 8.8 ± 4.6 7.2 ± 2.6 0.297
Platelet count (x109 / L) 109 ± 47 115 ± 48 89 ± 43 0.136
Renal function test
Serum creatinine (mg / dL) 0.85 ± 0.17 0.82 ± 0.16 0.97 ± 0.14 0.010
Plasma cystatin C (mg / L) 1.20 ± 0.41 1.08 ± 0.28 1.61 ± 0.53 0.013
Glomerular filtration rate
   CKD-EPI Cr (ml / min) 86.3 ± 18.3 91.3 ± 16.1 68.3 ± 14.2 < 0.001
   CKD-EPI CysC (ml / min) 68.3 ± 26.2 75.1 ± 24.0 43.8 ± 18.4 < 0.001
Liver function test
Total protein (g / dl) 6.8 ± 1.0 6.8 ± 1.0 6.7 ± 1.1 0.779
Serum albumin (g / dl) 2.4 ± 0.6 2.5 ± 0.6 2.1 ± 0.5 0.114
Total bilirubin (mg / dl) 3.2 ± 3.7 2.9 ± 3.4 4.3 ± 4.5 0.307
Direct bilirubin (mg / dl) 1.9 ± 2.7 1.6 ± 2.5 2.8 ± 3.5 0.209
AST (U/L) 86 ± 89 93 ± 98 61 ± 41 0.324
ALT (U/L) 49 ± 81 53 ± 91 34 ± 11 0.520
ALP (U/L) 157 ± 105 152 ± 72 173 ± 187 0.580
Coagulation test
INR 1.52 ± 0.42 1.42 ± 0.31 1.90 ± 0.55 0.024
Other
Uric acid (mg / dl) 6.8 ± 2.3 6.7 ± 2.6 6.9 ± 2.4 0.68
*The p-value of < 0.05 represents significant difference between survivors and non-survivors.
Abbreviations : CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration, Cr = creatinine, CysC = cys-
tatin C, WBC = white blood cell, AST = aspartate transaminase, ALT = alanine transaminase, ALP = alkaline 
phosphatase,  INR = international normalized ratio
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a significant association with the development of ACLF (OR 
6.07 ; 95%CI 1.31-28.20, p = 0.021). Plasma CysC as a predictor 
for development of in-hospital AKI, HRS, ACLF, and 90-day 
mortality was demonstrated in the Table 3. 
Table 4 shows univariate logistic regression analysis of factors 
associated with 90-day mortality. Baseline demographic data 
including severity of liver cirrhosis, type of decompensation, 
and initial laboratory parameters were included in the analy-
sis.  By univariate logistic regression analysis, age, MELD-Na 
score, bacterial infection on admission, SBP on admission, and 
plasma CysC level ≥ 1.25 mg / L were significantly associated 
with 90-day mortality. Taking into account that the number of 
event in this study was low, we therefore decided to include only 
3 factors in the multivariate regression model : age, bacterial 
infection, and plasma CysC level ≥ 1.25 mg / L. The MELD-Na 
score was excluded because it may collinear with plasma Cys C 
level given that both factors were based on the patients’ kidney 
function. Similarly, SBP was excluded because of its collinearity 
with bacterial infection.  As shown, after adjusting with age 
and bacterial infection, plasma CysC level ≥ 1.25 mg / L was in-
dependently associated with 90-day mortality with an adjusted 
OR of 6.70 (95%CI 1.05-42.73), however the statistical significant 
was borderline (p = 0.044).
 
DISCUSSION
This is a prospective observational study investigating the 
prognostic ability of plasma CysC in predicting in-hospital 
complications and 90-day mortality in acutely decompensated 
cirrhotic patients without AKI at admission. The data suggested 
that plasma CysC level within 24 hours after admission was sig-
nificantly higher in 90-day non-survivors, and it could be used as 
a reliable marker for prediction of in-hospital ACLF, and 90-day 
mortality in these patients. In addition, by multivariate analysis, 
plasma CysC ≥ 1.25 mg / L was an independent predictor of 90-
day mortality. 
Acute kidney injury frequently occurs as a complication lead-
ing to grave prognosis in decompensated cirrhosis (1, 2). These 
patients are generally susceptible to intravascular volume de-
pletion resulted from many conditions such as gastrointestinal 
bleeding, diarrhea, or sepsis-induced microvascular leakage (3). 
These precipitating events cause a decrease in effective arterial 
blood volume which can activate neurohormonal system, subse-
quently induce renal vasoconstriction, and contribute to AKI (3). 
Apart from precipitating factors, the severity of cirrhosis itself 
can provoke AKI through the mechanism of reduced renal blood 
flow due to portal hypertension in HRS (20). Our study demon-
strated a lower number of patients who developed in-hospital 
AKI compared with other study (10.9% vs. 53%) (21).  This could 
be explained by the fact that our study mainly comprised Child-
Pugh A cirrhosis with relatively low MELD score resulting in a 
lower rate of complications and mortality (22). However, another 
study revealed a comparable number of hospitalized decompen-
sated cirrhotic patients who later developed renal dysfunction 
(14%) during admission using different criteria for renal dys-
function (serum creatinine ≥ 1.5 mg / dL) (12). It should be noted 
that the demographic factors including age and male preponder-
ance of our cohort were almost similar to the previous study (12). 
Cystatin C has been recognized as a promising biomarker 
to evaluate renal function for several years (10). Studies have 
reported that it could overcome limitations of serum creatinine 
and facilitate early detection of AKI in cirrhotic patients (12-16). 
So far, few studies have evaluated the role of plasma CysC in 
hospitalized cirrhosis with acute decompensation (12, 15). The 
recent prospective study in hospitalized cirrhotic patients using 
CANONIC database has found that higher plasma CysC level 
was associated with the development of renal dysfunction, ACLF 
Table 3.　Plasma cystatin C as a predictor for development of in-hospital AKI, HRS, ACLF, and 90-day mortality
Outcome Cystatin < 1.25 mg / L(N = 29)
Cystatin ≥ 1.25 mg / L
(N = 17) Odds ratio (95% CI) P-value
AKI 1 (3.4%) 4 (23.5%) 8.62 (0.87-84.9) 0.065
HRS 0 2 (11.8%) - 0.131
ACLF 3 (10.3%) 7 (41.2%) 6.07 (1.31-28.20) 0.021
Death within 90 days 2 (6.9%) 8 (47.1%) 12 (2.14-67.24) 0.005
Abbreviations : AKI = acute kidney injury, HRS = hepatorenal syndrome, ACLF = acute-on chronic liver failur
Table 4.　Univariate and multivariate analysis of factors associated with 90-day mortality
Variables
Univariate analysis Multivariate analysis
OR (95% CI) P-value OR (95% CI) P-value
Age 1.11 (1.03-1.20) 0.006 1.07 (0.98-1.17) 0.133
Child-Pugh class A 1 -
Child-Pugh class B 2.18 (0.44-10.83) 0.341
Child-Pugh class C 1.89 (0.25-14.19) 0.537
MELD-Na 1.18 (1.02-1.37) 0.022
Bacterial infection 6.07 (1.31-28.2) 0.021 1.99 (0.29-13. 41) 0.477
SBP on admission 11 (1.98-61) 0.006
Plasma cystatin C ≥ 1.25 mg / L 12 (2.14-67.24) 0.005 6.70 (1.05-42.73) 0.044
Abbreviations : MELD = model for end-stage liver disease, SBP = spontaneous bacterial peritonitis
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and 90-day mortality (12). However, it should be noted that more 
than one-third of the included patients in the previous study had 
impaired renal function during the inclusion period. This fact 
potentially limits the clinical application of plasma CysC as an 
early marker of kidney injury in decompensated cirrhosis if one 
already had impaired renal function at baseline. Therefore, our 
study aimed to explore the predictive ability of plasma CysC in 
decompensated cirrhosis who had no AKI at admission. In the 
present study, we found that the mean plasma CysC was higher 
in patients who died within 90 days compared with those who 
were alive. Moreover, patients who developed in-hospital AKI, 
HRS and ACLF tended to have higher CysC level than patients 
without these conditions. The mean CysC values of patients who 
had in-hospital AKI and HRS (1.82 and 2.03 mg / L, respectively) 
were quite comparable to what have been reported in the ear-
lier study (1.6 and 2.1 mg / L, respectively) (12). In addition, we 
demonstrated that the cut-off value of plasma CysC level ≥ 1.25 
mg / L yielded the best sensitivity for prediction of 90-day mortal-
ity. The cut-off point was slightly lower than previously reported, 
which could be possibly attributed to variability of patients in-
cluded and ethnic diversity(12). 
Most of patients (80%) who developed in-hospital AKI in this 
study had elevated plasma CysC but normal serum creatinine 
level on the first day of admission. This suggested that elevated 
baseline plasma CysC level could predict AKI earlier than a rise 
in serum creatinine in hospitalized decompensated cirrhotic 
patients.  In addition to renal outcomes, this study disclosed an 
association between higher CysC level and the development of 
ACLF. This information is clinically relevant as ACLF patients 
carry an exceptionally high morbidity and mortality rates (17). 
Therefore, an early identification of ACLF by a simple and reli-
able biomarker should be encouraged. Supporting this idea, in 
the present study, all ACLF patients died within 90 days indicat-
ing an ominous prognosis especially when renal failure was one 
of end organ damage.
Mortality rate has long been a primary focus in cirrhosis 
research field. Patients with compensated cirrhosis has re-
markably longer median survival time than the decompensated 
ones ( > 12 vs. 2 years, respectively) (23). The transition from 
compensated to decompensated cirrhosis can be accelerated by 
complications at any time during the disease course. Our study 
revealed a slightly lower 90-day mortality rate than prior stud-
ies, which might be caused by a higher number of patients with 
early cirrhosis included in the present study (12, 24). Regarding 
causes of death, sepsis with multiorgan failure was the most 
frequent cause, which was similar to what has been previously 
reported (23). In the present study, we have demonstrated that, 
in the multivariate regression analysis, after adjusting with age 
and bacterial infection on admission, plasma CysC level was sig-
nificantly associated with 90-day mortality. This finding empha-
sizes a potential advantage of plasma CysC level as a predictor 
for short-term mortality. However, taking into consideration that 
the statistical significance level was marginal, more data are 
needed to clarify this issue. 
Another point worth mentioning in the present study was that 
bacterial infection and SBP were significantly associated with 
90-day mortality in the univariate analysis. It is well known 
that bacterial infection is very common among hospitalized 
cirrhotic patients, and is associated with an increase risk of 
mortality (25). From the pathophysiological standpoint, bacterial 
infection is distinct from other decompensations given that it can 
cause an exaggerated systemic inflammation that is responsible 
for organ failure in patients with cirrhosis (26). Of note, a recent 
global scale study has demonstrated that 48% of ACLF patients 
were documented with bacterial infection, of which the majority 
were SBP, pneumonia, and infections caused by multidrug-resis-
tant organisms (27). 
There were some limitations in this study. First, our study 
had a relatively small sample size, however, the number of par-
ticipants exceeded the minimum number determined by sample 
size calculation. Second, AKI was diagnosed by International 
Club of Ascites definitions based on serum creatinine, which 
could underestimate renal dysfunction in cirrhotic patients. 
However, serum creatinine is the most widely used biomarker 
of kidney function in clinical practice. Third, our study lacked 
validation cohort. Therefore, our results including the optimal 
cut-off point of plasma CysC need to be redetermined in the 
future study. Finally, the result of the ROC analysis showing 
that plasma CysC was superior to the MELD score for 90-day 
mortality prediction should be interpreted with caution because 
the sample size and the event rate in the present may be too 
small for the ROC analysis, as well as the significance level was 
considerably borderline. 
In conclusion, plasma cystatin C within 24 hours after admis-
sion can be used as a renal biomarker for prognostic prediction 
of 90-day mortality, and the development of in-hospital ACLF in 
hospitalized decompensated cirrhotic patients who have no AKI 
at admission. This information could facilitate early identifica-
tion and raise awareness of ACLF in these patients.
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